Ruibi Bio Raises Tens of Millions in Series A Funding to Advance Innovative Electromagnetic Oncology Therapy Platform

Recently, VCBeat (WeChat: vcbeat) learned that Hangzhou Ruidi Biotechnology Co., Ltd. has recently completed a Series A financing round worth tens of millions of yuan, invested by Proxima Capital and Sanjie Capital. Li Zhe, Partner at Proxima Capital, has joined the board of directors.

Hangzhou Ruidi Biotechnology Co., Ltd. specializes in the application of electromagnetic technology for tumor treatment. The company has mastered key technologies such as pulse design and control, and has developed independently innovated tumor treatment devices suitable for treating malignant tumors including liver cancer and pancreatic cancer. Compared with internationally available electromagnetic ablation products used in clinical practice, Ruidi Biotechnology’s novel electromagnetic diagnosis and treatment technology offers higher therapeutic efficiency, lower surgical risk, and reduced costs, while also showing potential to reduce tumor invasion, metastasis, and recurrence. Supported by China’s National Major Science and Technology Projects, the company’s first product is about to initiate multi-center clinical trials. Ruidi Biotechnology has the potential to become the world’s first company to achieve industrialization of this novel electromagnetic tumor ablation technology. Leveraging its electromagnetic platform technology, the company has multiple products under development and aims to establish a comprehensive innovative solution for electromagnetic tumor therapy in the future.

Dr. Chen Xinhua, founder of Ruidi Biotechnology, stated, “We are delighted to partner with investors Proxima Capital and Sanjie Capital to jointly provide better innovative therapies for clinical practice! The successful completion of this financing round reflects the significant progress Ruidi Biotechnology has made in advancing its innovative development over the past few years, leading the research, development, and transformation of a new generation of electromagnetic medical products.”

As an investor in this funding round, Proxima Capital stated, “We are optimistic about the application of electromagnetic technology in tumor treatment, particularly favoring Ruidi Biotechnology’s leading technology platform and its team’s extensive clinical experience. We look forward to seeing Ruidi Biotechnology’s product portfolio enter the market as soon as possible, enabling more cancer patients in China to access safe, effective, and more cost-effective innovative treatment options.”